An Effective Hypoxia-Related Long Non-Coding RNAs Assessment Model for Prognosis of Clear Cell Renal Carcinoma

Han Zhang1,2†, Chuan Qin3†, Hua Wen Liu2, Xiong Guo4 and Hua Gan1*

1 Department of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, 2 Department of Oncology, Chongqing University Three Gorges Hospital, Chongqing, China, 3 Department of Gastrointestinal Surgery, Chongqing University Three Gorges Hospital, Chongqing, China, 4 Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Hypoxia is a significant clinical feature and regulates various tumor processes in clear cell renal carcinoma (ccRCC). Increasing evidence has demonstrated that long non-coding RNAs (lncRNAs) are closely associated with the survival outcomes of ccRCC patients and regulates hypoxia-induced tumor processes. Thus, this study aimed to develop a hypoxia-related lncRNA (HRL) prognostic model for predicting the survival outcomes in ccRCC. LncRNAs in ccRCC samples were extracted from The Cancer Genome Atlas database. Hypoxia-related genes were downloaded from the Molecular Signatures Database. A co-expression analysis between differentially expressed lncRNAs and hypoxia-related genes in ccRCC samples was performed to identify HRLs. Univariate and multivariate Cox regression analyses were performed to select nine optimal lncRNAs for developing the HRL model. The prognostic model showed good performance in predicting prognosis among patients with ccRCC, and the validation sets reached consistent results. The model was also found to be related to the clinicopathologic parameters of tumor grade and tumor stage and to tumor immune infiltration. In conclusion, our findings indicate that the hypoxia-lncRNA assessment model may be useful for prognostication in ccRCC cases. Furthermore, the nine HRLs included in the model might be useful targets for investigating the tumorigenesis of ccRCC and designing individualized treatment strategies.

Keywords: clear cell renal carcinoma, hypoxia, long non-coding RNA, prognosis, biomarker

INTRODUCTION

Renal cell carcinoma (RCC) causes more than 100,000 deaths per year (1). Although target therapy and immunotherapy have improved the prognosis of RCC patients (2), the 5-year survival rate remains less than 10%. Clear cell renal cell carcinoma (ccRCC) is the main subtype of RCC, accounting for 70–75% of all RCC cases (3). In clinical practice, the prognosis and treatment of
ccRCC are primarily based on the tumor stage. However, the outcomes still vary among patients with the same tumor stage because of molecular heterogeneity (4). Therefore, it is vital to identify individualized biomarkers that can identify patients at high risk of death and help stratify patients for individual treatment to optimize the therapeutic effect.

Hypoxia refers to a reduction of oxygen availability at the cell level, including in tumors (5). As a significant clinical feature, hypoxia regulates various tumor processes, including angiogenesis, cell proliferation, invasion, apoptosis, and radiochemotherapy resistance (6). Hypoxia adaption is a key factor in tumor progression and has been proven to be a cause of treatment failure (7).

Long non-coding RNAs (lncRNAs) are untranslated RNAs of >200 nucleotides in length (8). They have recently attracted increasing research attention because of their involvement in several key molecular and biologic processes (9, 10). For example, lncRNAs regulate hypoxia-related tumor processes (11). In RCC, IncRNA-SARCC can regulate tumor cell proliferation through the androgen receptor/HIF-2α/C-MYC axis under hypoxia (12). IncRNA EGOT can also regulate autophagy under hypoxia in renal tubular cells (13). Therefore, a hypoxia-related IncRNA (HRL)-based prognostic model may be potentially useful in ccRCC.

As such, this study aimed to develop a HRL prognostic model for predicting the survival outcomes in ccRCC.

**MATERIALS AND METHODS**

**Data Source**

Transcriptome expression profiles for patients with ccRCC were obtained from The Cancer Genome Atlas database (TCGA), https://cancergenome.nih.gov/ on June 29, 2020 (14). The expressions were quantified with fragments per kilobase of exon per million reads mapped. The corresponding clinical information of the patients from whom the samples were obtained was also downloaded from the database, which included age, sex, tumor grade, tumor stage, and survival (Table 1). Patients with incomplete information or <30 days of data were excluded because they might have died because of acute complications, rather than of the cancer itself.

Data on hypoxia-related genes were collected from the Molecular Signatures Database V7.2 (https://www.gsea-msigdb.org/gsea/msigdb, Hypoxia M10508, Hypoxia cancer M7547) (15). If the expression data of the gene are not detected in more than 50% of the samples, the gene is excluded. Immune infiltration data were collected from CIBERSORT (https://cibersort.stanford.edu/) (16), which contains abundances of 22 types of tumor-infiltrating immune cells, namely, naive B cells, memory B cells, plasma cells, CD8 T cells, naive CD4 T cells, resting memory CD4 T cells, activated memory CD4 T cells, follicular helper T cells, T cells regulatory, gamma delta T cells, resting NK cells, activated NK cells, monocytes, macrophages M0, macrophages M1, macrophages M2, resting dendritic cells, activated dendritic cells, resting mast cells, activated mast cells, eosinophils, and neutrophils.

**Definition of Hypoxia-Related Long Non-Coding RNAs**

Genes were identified as protein-coding genes or lncRNAs according to their Ensembl IDs. The lncRNAs were further screened via the Genecards database (https://www.genecards.org/) (17). We excluded the lncRNAs recognized as “Pseudogene,” “Uncatogitized,” and “No results” in the database. Differentially expressed lncRNAs between the kidney and healthy renal tissue were identified via the differential-expression analysis using the R package “limma” (log2 fold-change [logFC] of >1 and an adjusted false-discovery rate [FDR] of <0.05) (18). Heatmaps and volcano plots were used to visualize the differentially expressed lncRNAs via the R package “pheatmap.” (19)

We then performed co-expression analysis between hypoxia genes and differentially expressed lncRNAs based on the Spearman correlation analysis (20, 21). LncRNAs with a Spearman correlation coefficient ≥0.4 and a P-value ≤0.001 were identified as HRLs.

**Development of the Hypoxia Long Non-Coding RNA-Related Prognostic Model**

All the samples were randomly divided into the training dataset and the 1st validation dataset at the ratio of 1:1. Then the samples
were randomly divided into the 2nd validation dataset and 3rd validation dataset at the ratio of 3:7. The training dataset was used to construct the HRL-related prognostic model to predict the prognosis for ccRCC patients. Univariate Cox regression analyses were used to extract the hypoxia survival-associated lncRNAs via the R package “survival” (significant at P ≤ 0.01). A Cox proportional hazards model with a lasso penalty analysis was used to construct the HRL model with the optimal prognostic value via the R packages “glmnet” and “survival.” (22) The risk score of each sample was calculated based on the regression coefficients from the model and lncRNAs’ expression. The formula is below:

\[
\text{Risk score (patient)} = \sum_{k=1}^{n} (\text{coef} \times \text{exp})
\]

with “n” representing the number of lncRNA; “k,” the serial number of each lncRNA; coef, the coefficient value from the Cox proportional hazards analysis; and exp, the expression of the lncRNA (23).

**Validation of the Model**

The validation datasets were used to validate the predictive power of the HRL-related model. In each dataset, patients were assigned to the low- and high-risk groups based on the median risk scores. Kaplan–Meier survival curve analyses and log-rank tests were performed to evaluate the predictive power of the model for overall survival (OS), using the R package “survival” and “survminer.” Receiver operating characteristic (ROC) curves (24) and area under the ROC curves (AUC) were calculated to assess the accuracy of the model, using the R package “survivalROC.” An AUC of >0.75 was judged as excellent predictive value. Univariate and multivariate analyses via the R package “survival” were also performed to verify the independent prognostic predictors. The nomogram was plotted using the R package “rms.” (25)

**Gene Set Enrichment Analysis**

Gene set enrichment analysis (GSEA) (version 4.0.1, http://www.broadinstitute.org/gsea) was performed to identify differences in the set of genes expressed between the low- and high-risk groups in the enrichment of Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) data. Gene set permutations were performed 1,000 times for each analysis.

**Statistical Analysis**

All statistical analyses were performed using the R software (version 3.6.1, http://www.R-project.org). The PERL programming language (version, 5.30.2, http://www.perl.org) was used to process data. The Wilcoxon signed-rank test was used for identifying differentially expressed lncRNAs and tumor-infiltrating immune cells. The Spearman correlation analysis was used for identifying HRLs. The Kaplan–Meier method and log-rank test were performed to compare the OS between the high- and low-risk groups.

**RESULTS**

**Hypoxia-Related Long Non-Coding RNAs in Clear Cell Renal Carcinoma**

A total of 14,143 lncRNAs were extracted from the TCGA database. We identified 1,926 differentially expressed lncRNAs in renal cancer specimens (n = 539) and normal renal specimen (n = 72) (logFC of >1 and FDR of <0.05) (Figures 1A, B).

![Figure 1](https://example.com/figure1.png)

**FIGURE 1**  
(A) Heatmap and (B) volcano diagram of the Wilcoxon signed-rank test showing the differentially expressed lncRNAs between clear cell renal carcinoma and normal tissue samples. The red, green, and black dots represent the upregulated lncRNAs, downregulated lncRNAs, and no difference, respectively.
Among these lncRNAs, 186 lncRNAs were excluded due to the lack of definition in the Genecards database.

Of the 137 hypoxia genes obtained from the Molecular Signatures Database V7.2, four genes (FGF3, LIN28B, MMP13, and TH) were excluded owing to a lack of over 50% expression information. In total, 598 HRLs were confirmed by co-expression analyses between hypoxia genes and differentially expressed lncRNAs (P ≤ 0.001, Spearman correlation coefficient ≥ 0.4).

**Construction of Hypoxia Long Non-Coding RNA-Related Prognostic Model**

After excluding patients without cancer or survival data, we merged the survival data with lncRNA expression data of each patient. We then divided the remaining patients into the training dataset (n = 255) and the 1st validation dataset (n = 252) at the ratio of 1:1 and divided the patients into the 2nd validation dataset (n = 153) and the 3rd validation dataset (n = 354) at the ratio of 3:7. The risk model was developed using the training dataset and validated using the validation datasets.

Univariate cox regression analyses were first performed for the hypoxia differentially expressed lncRNAs, and the results showed that 163 lncRNAs were significantly related to the OS of ccRCC (P ≤ 0.01). A Cox proportional hazards model with a lasso penalty analysis was further performed to construct the optimal risk model (Figures 2A, B). Ultimately, nine optimal prognostic HRLs were obtained and incorporated into the risk model: ITPR1-DT, AC008760.2, AC084876.1, AC002070.1, LINC02027, AC147651.1, FOXD2-AS1, LINC00944, and LINC01615 (Figure 2C). The risk score for each patient was calculated as: risk score = (0.271 × ITPR1-DT expression) + (0.011 × AC008760.2 expression) + (0.546 × AC084876.1 expression) + (−0.514 × AC002070.1 expression) + (−0.173 × LINC02027 expression) + (−0.027 × AC147651.1 expression).

![FIGURE 2](A) The LASSO Cox regression model to identify the most robust lncRNAs. (C) Forest plot of the multivariate Cox regression model showing the nine optimal prognostic hypoxia-related lncRNAs. * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001.
(expression) + (0.286 × FOXD2-AS1 expression) + (0.161 × LINC00944 expression) + (0.065 × LINC01615 expression).

Validation of the Prognostic Score

To verify the accuracy of prognostic prediction of each patient, we performed ROC in the training dataset and the validation datasets. In the training dataset, the AUCs for predicting the 3-, and 5-year survival were 0.805, and 0.802, respectively, indicating excellent prognostic power (Figures 3A, B). Similar results were obtained in the 1st (Figures 3C, D), 2nd (Figures 3E, F) and 3rd (Figures 3G, H) validation datasets.

The patients were then divided into the high- and low-risk groups using the median risk score as a cut-off. Kaplan–Meier curves were plotted in the training dataset, and the results showed poorer survival in the high-risk group than in the low-risk group (P = 1.922e-10) (Figure 4A). The survival analyses in the validation groups also revealed poorer survival in the high-risk groups than in the low-risk groups [3.078e-08 in the 1st validation dataset].

![FIGURE 3](image-url) | Survival-dependent receiver operating characteristics (ROC) for predicting survival in the datasets. ROC for predicting the (A) 3-year, and (B) 5-year survival in the training dataset. ROC for the (C) 3-year, and (D) 5-year survival in the 1st validation dataset. ROC for predicting the (E) 3-year, and (F) 5-year survival in the 2nd dataset. ROC for predicting the (G) 3-year, and (H) 5-year survival in the 3rd validation dataset.
(Figure 4B), 2.043 e-08 in the 2nd (Figure 4C), and 1.946e-10 in the 3rd validation dataset (Figure 4D).

The risk score distributions, survival status, and risk gene expressions in each dataset are shown in Figure 5. The low-risk groups had obviously higher survival rate (Figure 5A) and lower values for the risk score (Figure 5C) in the training dataset. Moreover, as the risk score increased, the expressions of the protective IncRNAs (AC008760.2, LINC00944, LINC01615, ITPR1-DT, AC084876.1, and FOXD2-AS1) decreased, whereas those of the risk IncRNAs (AC147651.1, LINC02027, and AC002070.1) increased (Figure 5E) in the training dataset. Similar results were obtained in the 1st (Figures 5B, D, F), 2nd (Figures 5G, I, K) and 3rd (Figures 5H, J, L) validation datasets.

In the univariate analysis to evaluate the relationship between clinical characteristics and OS, the TNM stage was excluded because several patients had missing information. The results showed that age (P = 0.003), tumor grade (P = 0.031), tumor stage (P < 0.001), and risk score (P < 0.001) were significantly associated with prognosis (Figures 6A, C, E, G). Multivariate analysis confirmed age, tumor stage, and risk score as independent prognostic factors (Figures 6B, D, F, H). In addition to risk score, age and tumor stage could also divide patients into high- and low-risk groups effectively (Supplementary Figure 1). To further verify the predictive power of our risk score in the patients with same tumor stage, we divided early stage (I and II) and advanced stage (III and IV) ccRCC patients into the high- and low-risk groups using the median risk score. Kaplan–Meier curves were plotted in two groups, and the results showed poorer survival in the high-risk groups than in the low-risk groups (Supplementary Figure 2).

The independent prognostic factors (age, tumor stage, and risk score) were used to develop the nomogram for predicting the 1-, 3-, and 5-year prognoses of the patients (Figure 7A). Similar results were obtained in the validation datasets (Supplementary Figure 3). In the nomogram, we can calculate the point of each factor and the total points of all factors. The 1-, 3-, and 5-year survival rates could be predicted by the corresponding value of total points.

### Clinical Utility of the Risk Score

The association among the risk IncRNAs (ITPR1-DT, AC008760.2, AC084876.1, AC002070.1, LINC02027, AC147651.1, FOXD2-AS1, LINC00944, and LINC01615), risk score, and clinicopathologic parameters (age, sex, tumor grade, and tumor stage) was analyzed in the training dataset (Table 2). The risk score was obviously higher in samples with high-grade and advanced-stage tumor (Figures 7B, C). Similar results were obtained in the validation datasets (Supplementary Tables).
This finding supports that the risk score can also reflect tumor progression. To explore which pathways were enriched, we used GSEA software to perform KEGG (Figures 8A, B) and GO analysis (Figures 8C, D). KEGG analysis identified multiple tumor-related signaling pathways in the high-risk group, such as homologous recombination, Base excision repair, and cytokine-cytokine receptor interaction. Surprisingly, "KRG" and GO analysis identified that several immune-related signal pathways and genes were enriched in the samples.

We further analyzed the correlation between immune cell infiltration and the risk score. First, we plotted the immune landscape of all the samples, as shown in Figure 9A. Then, we analyzed the difference in the number of immune cells between the low- and high-risk groups for all the samples. We identified six types of immune cells with differences in infiltration between the two groups, namely, plasma cells, follicular helper T cells, regulatory T cells, M2 macrophages, resting dendritic cells, and resting mast cells (Figure 9B).

**DISCUSSION**

Despite advances in diagnosis and treatment, ccRCC as a lethal RCC subtype remains to have poor prognosis (26). Further, current prognostic models for ccRCC have limited predictive capability because of the complex molecular heterogeneity of this
malignancy. Hence, in this study, we identified a novel prognostic model for predicting ccRCC outcomes.

Hypoxia has been confirmed to be closely related to tumorigenesis and tumor progression of ccRCC (27). Previous studies have established that lncRNAs are involved in tumorigenesis, tumor progression, and metastasis (28–30). In this study, HRLs were related to the survival outcomes of patients with ccRCC, and thus we developed an HRL-related model to predict ccRCC prognosis. To our best knowledge, this is the first study to develop such predictive model for ccRCC.

Previous studies suggested that lncRNAs are involved in multiple processes in ccRCC (31, 32). For example, lncRNA UCA1 plays an oncogenic role in RCC by regulating the miR-182-5p/DLL4 axis (33). LncRNA URRCC can also promote the proliferation and metastasis of ccRCC by regulating the P-AKT signaling pathway (34). Further, lncRNA OTUD6B can inhibit
ccRCC cell proliferation by suppressing the Wnt/β-catenin pathway and the expressions of epithelial-to-mesenchymal transition-related proteins (35). In this study, we screened 1926 differentially expressed lncRNAs in ccRCC tissue, relative to the levels in adjacent normal renal tissue. The results indicated that lncRNAs are closely related to the tumorigenesis of ccRCC, in agreement with previous findings.

Tumor hypoxia is defined as lower oxygenation in solid tumors than in normal tissues. Hypoxia can lead to resistance to chemoradiotherapy and target therapy (7, 36); increases angiogenesis and vasculogenesis (37), thus predisposing to tumor metastases; and contributes to altered metabolism and genomic instability. LncRNAs have been reported be involved in the development of ccRCC by regulating the hypoxia pathway. For
example, Hamilton et al. found that lncRNA HOTAIRM1 inhibited the hypoxia pathway in ccRCC (38). Zhang et al. revealed that under hypoxic conditions in ccRCC, lncRNA CRPAT4 promoted cell migration by regulating AVL9 (39). In the present study, we performed a co-expression analysis between hypoxia genes and differentially expressed lncRNAs through paired lncRNA and mRNA expression data in ccRCC patients from TCGA. A total of 598 lncRNAs were extracted and defined as HRLs. The close association between hypoxia genes and HRLs in ccRCC samples indicate that HRLs are involved in the development of ccRCC. Among all the HRLs, nine lncRNAs (i.e., ITPR1-DT, AC008760.2, AC084876.1, AC002070.1, LINC02027, AC147651.1, FOXD2-AS1, LINC00944, and LINC01615) were identified to be independently associated with prognosis and were thus used to develop the prognostic model. ROC curves confirmed the good specificity and sensitivity of the HRL-based prognostic model. Kaplan-Meier survival curves showed excellent efficiency of our HRL-related model in stratifying patients with different risks of mortality. Multivariate analyses demonstrated that the age, tumor stage and the risk score were independent prognostic factors. We further identified the prognostic predictive power of our risk score in the patients with same tumor stage. Hence, our HRL-related model maybe useful as a supplement to the tumor stage for better stratifying patients and for providing a more individualized approach to treatment. We further developed a nomogram by integrating age, tumor stage, and risk score. From it we can easily obtain a single number, which reflects survival when accounting for these three factors.

Tumor hypoxia also changes the interaction and cross-talk of cancer cells with the surrounding tumor microenvironment, leading to immune resistance and immune suppression, which help tumor cells escape immune surveillance (5, 40, 41). To determine whether our HRL-related model can also reflect the tumor microenvironment, we performed GSEA. The results showed that several immune-related GO terms or signaling pathways were enriched in the high-risk group. We further plotted the immune landscape of each ccRCC sample for exploring the tumor immune microenvironment in patients with ccRCC. Then, we compared the infiltration of every immune cell type between the high- and low-risk groups. Plasma cells, follicular helper T cells, regulatory T cells, M2 macrophages, resting dendritic cells, and resting mast cells were found to be differentially infiltrated in ccRCC, which are closely associated with tumorigenesis, progression, and metastasis (42–46). This finding supports that our HRL-related model can partly reflect immune infiltration and provide valuable information for immunotherapy.

The whole process of our analyses was based on the data from TCGA database, which contains complete clinical and survival data of patients with ccRCC. It also has sufficient ccRCC samples to be divided into a training dataset and validation datasets. Therefore, a prognostic model constructed using TCGA database has better statistical power than a model constructed using patient samples derived from a single institution. However, the current study still has some limitations. First, we haven’t found an available independent lncRNA dataset to validate the usefulness of our prognostic model, and we were not able to
validate in clinical practice owing to the lack of ccRCC samples. Second, the relationship between the nine lncRNAs and ccRCC remains unclear to date because of the limited number of lncRNA researches. The validity of our prognostic model should be evaluated in further research with a large number of clinical samples and with adequate follow-up duration. In addition, the underlying mechanisms by which lncRNAs influence the prognosis of ccRCC should be investigated in in vivo and in vitro experiments.

CONCLUSION

Our hypoxia-lncRNA assessment model may be useful to improve the prognostic prediction of ccRCC patients with the same tumor stage. Furthermore, the nine HRLs included in the model might be useful targets for investigating the tumorigenesis of ccRCC and designing personalized individualized treatment strategies.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. These data can be found here: The Cancer Genome Atlas (https://portal.gdc.cancer.gov/), the Molecular Signatures Database V7.2 (https://imimport.niaid.nih.gov), CIBERSORT (https://cibersort.stanford.edu/).

AUTHOR CONTRIBUTIONS

HZ and HG designed the study. HZ and CQ collected and analyzed the data, and drafted the manuscript. CQ and HL made the figures and tables. XG provided critical suggestions regarding the figures and manuscript. HG led the research team. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We would like to thank Editage (www.editage.cn) for English language editing.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.616722/full#supplementary-material

Supplementary Figure 1 | (A) Kaplan–Meier curves of overall survival for the young (≤50 y) and elderly (>50 y) groups. (B) Kaplan–Meier curves of overall survival for the early (I–II) and advanced (III–IV) tumor stage groups.

Supplementary Figure 2 | Kaplan–Meier curves of overall survival for the highrisk and low-risk groups according to the median risk score. (A) ccRCC patients with early tumor stages (I–II) and (B) advanced stages (III–IV).
REFERENCES

1. Hsieh J, Purdue M, Signoretti S, Swanton C, Albiger L, Schmидinger M, et al. Renal cell carcinoma. *Nat Rev Dis Primers* (2017) 3:17009. doi: 10.1038/nrdp.2017.9

2. Haddad A, Margulis V. Tumour and patient factors in renal cell carcinoma—towards personalized therapy. *Nat Rev Urol* (2015) 12(5):253–62. doi: 10.1038/nrurol.2015.71

3. Störlk S, Eble J, Adlakha K, Amin M, Blute M, Bostwick D, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). *Cancer* (1997) 80(5):987–9. doi: 10.1002/(sici)1097-0142(19970901)80:5<987::aid-cncr24>3.0.co;2-r

4. Molina A, Lin X, Korytowsky B, Matczak E, Lechuga M, Wiltshire R, et al. Suntinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. *Eur J Cancer* (Oxford Engl) (2014) 50(2):351–8. doi: 10.1016/j.ejca.2013.08.021

5. Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. *Mol Cancer* (2019) 18(1):157. doi: 10.1186/s12953-019-0988-6

6. Park S, Corneanu A, Pouysségur J. Hypoxia and cellular metabolism in tumour pathophysiology. *J Physiol* (2017) 595(8):2439–50. doi: 10.1113/ jph237309

7. Zhao C, Luo C, Wu X. Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2. *Med Oncol* (Northwood London England) (2015) 32(1):419. doi: 10.1007/s12302-014-0419-4

8. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell biology and disease. *Nat Rev Genet* (2015) 14(1):7–21. doi: 10.1038/nrg3666

9.芫 H, Gao C, Liu L, Zhuang J, Yang J, Liu C, et al. 7-lncRNA Assessment for the functional interplay of lncRNA EGOT and HuR regulates hypoxia-induced autophagy in renal tubular cells. *J Cell Biochem* (2020) 121(11):4522–34. doi: 10.1002/jcb.29669

10. Choudhry H, Harris A, McIntyre A. The tumour hypoxia induced non-coding transcriptome. *Mol Aspects Med* (2016) 47–48:35–53. doi: 10.1016/j.mam.2016.01.003

11. Zhai W, Sun Y, Jiang M, Wang M, Gasiewicz T, Zheng J, et al. Differential regulation of lncRNA-SARC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia. *Oncogene* (2016) 35(37):4866–80. doi: 10.1038/onc.2016.19

12. Wang I, Palanisamy K, Sun K, Yu S, Yu T, Li C, et al. The functional interplay of IncRNA EGOT and HuR regulates hypoxia-induced autophagy in renal tubular cells. *J Cell Biochem* (2020) 121(11):4522–34. doi: 10.1002/jcb.29669

13. Liu J, Lichtenberg T, Haidle K, Pissoson L, Lazar A, Cherniack A, et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell* (2018) 173(2):400–16.e11. doi: 10.1016/j.cell.2018.02.052

14. Liberton A, Binger C, Thorvilddottir H, Ghandi M, Mesirov J, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst* (2015) 1(6):417–25. doi: 10.1016/j.cels.2015.12.004

15. Chen B, Khodadoust M, Liu C, Newman A, Alizadeh A. Profiling Infiltrating Immune Cells with CIBERSORT. *Methods Mol Biol* (Clifton NJ) (2018) 1711:243–59. doi: 10.1007/978-1-4939-7493-1_12

16. Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmish M, et al. GenCards Version 3: the human gene integrator. *Database J Biol Database Curation* (2010) 2010:bqq020. doi: 10.1093/database/bqq020

17. Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* (2015) 43(7):e47. doi: 10.1093/nar/gku007

18. Li W. Volcano plots in analyzing differential expressions with mRNA microarrays. *J Biostat Comput Biol* (2012) 10(6):1231003. doi: 10.1142/ s0219720012310038

19. Chen S, Lin F, Zhu J, Ke Z, Lin T, Lin Y, et al. An immune-related lncRNA prognostic model in papillary renal cell carcinoma: An lncRNA expression analysis. *Genomics* (2020) 113:531–40. doi: 10.1016/j.ygeno.2020.09.046
clear cell renal cell carcinomas. *OncoTargets Ther* (2018) 11:4537–45. doi: 10.2147/ott.S169155

40. Kumar V, Gabrilovich D. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. *Immunology* (2014) 143(4):512–9. doi: 10.1111/imn.12380

41. Noman M, Hasmim M, Lequeux A, Xiao M, Duhem C, Chouaib S, et al. Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. *Cells* (2019) 8(9):1083. doi: 10.3390/cells8091083

42. Zhang H, Yue R, Zhao P, Yu X, Li J, Ma G, et al. Proinflammatory follicular helper T cells promote immunoglobulin G secretion, suppress regulatory B cell development, and correlate with worse clinical outcomes in gastric cancer. *Tumour Biol J Int Soc Oncodevelopmental Biol Med* (2017) 39(6):1010428317705747. doi: 10.1177/1010428317705747

43. Ngabire D, Niyonzimiyi I, Patil M, Seong Y, Seo Y, Kim G. BM2 Macrophages Mediate the Resistance of Gastric Adenocarcinoma Cells to 5-Fluorouracil through the Expression of Integrin 3, Focal Adhesion Kinase, and Collin. *J Immunol Res* (2020) 2020:1731457. doi: 10.1155/2020/1731457

44. Ling Z, Shao L, Liu X, Cheng Y, Yan C, Mei Y, et al. Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study. *Front Immunol* (2019) 10:533. doi: 10.3389/fimmu.2019.00533

45. Bagheri V, Abbasszadegan M, Memar B, Motie M, Asadi M, Mahmoudian R, et al. Induction of T cell-mediated immune response by dendritic cells pulsed with mRNA of sphere-forming cells isolated from patients with gastric cancer. *Life Sci* (2019) 219:136–43. doi: 10.1016/j.lfs.2019.01.016

46. Aponte-López A, Muñoz-Cruz S. Mast Cells in the Tumor Microenvironment. *Adv Exp Med Biol* (2020) 1273:159–73. doi: 10.1007/978-3-030-49270-0_9

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhang, Qin, Liu, Gao and Gan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.